Pharming Group N.V. PHAR
As ofNov 20, 2026, 3:26 PM EST
- YTD
- -34.72%
- 1 year
- -29.02%
5D -0.50 (-3.94%)
- Market cap
- 816.43M
- Revenue (ttm)
- 369.49M
- Profit margin
- 3.34%
- EPS (ttm)
- 0.32
- Shares out
- 70.63M
- P/E ratio
- 36.05
- Forward P/E
- 216.49
- YTD return
- -34.72%
- 1-year return
- -29.02%
- Volume
- 8.60K
- Avg volume
- 21.34K
- Open
- 11.85
- Previous close
- 12.16
- Day's range
- 11.30 – 11.97
- 52-week range
- 9.11 – 21.34
- Beta
- 0.09
- Analysts
- Strong Buy
- Price target
- 34.35 (+197.8%)
Key statistics
- 50-day average
- 13.57
- 200-day average
- 15.63
- Enterprise value
- 1.01B
- Price / sales
- 2.71
- Price / book
- 3.93
- Revenue growth
- -8.40%
- Free cash flow
- 59.02M
- Total cash
- 170.18M
- Total debt
- 116.20M
- Return on equity
- 5.04%
- Short % of float
- 0.01%
Fundamental scorecard
15 of 25 checks passed on PHAR’s reported financials
15of 25 checks passed
- Value 4 of 5
- Growth 3 of 5
- Profitability 3 of 5
- Financial health 5 of 5
- Dividend No data
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | 0.10 | — | — | — |
| Jul 30, 2026 | Jun 30, 2026 | 0.063 | 0.02 | -0.04 | -68.25% |
| May 7, 2026 | Mar 31, 2026 | 0.05 | -0.07 | -0.12 | -240.00% |
| Mar 12, 2026 | Dec 31, 2025 | 0.15 | 0.07 | -0.08 | -53.33% |
| Nov 6, 2025 | Sep 30, 2025 | 0.05 | 0.10 | +0.05 | +100.00% |
| Jul 31, 2025 | Jun 30, 2025 | -0.10 | 0.06 | +0.16 | +160.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 10, 2026 | Canaccord Genuity | init | — | Buy |
| Mar 24, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Mar 13, 2026 | Oppenheimer | reit | Outperform | Outperform |
| Mar 21, 2025 | HC Wainwright & Co. | reit | Buy | Buy |
| Mar 20, 2025 | HC Wainwright & Co. | reit | Buy | Buy |
| Mar 14, 2025 | Oppenheimer | main | Outperform | Outperform |
About Pharming Group N.V.
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K? inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Netherlands
- Website
- pharming.com
News
Pharming Receives U.K. Approval For Joenja In Children Aged 4 To 11 With APDS, Supported By Pediatric Clinical Program Data; Marks Step In Expansion Across Age Groups And Markets
Canaccord Genuity Maintains Buy on Pharming, Raises Price Target to $41
Pharming Q3 2026 Earnings Call Transcript Pharming Affirms FY2026 Sales Guidance of $380.000M-$390.000M vs $383.333M Est
Pharming Q3 EPS $0.30 Beats $0.02 Estimate, Sales $117.600M Miss $117.733M Estimate
Selective Insurance, Crown Castle, UWM Holdings And Other Big Stocks Moving Higher On Friday
Crude Oil Moves Higher; Lockheed Martin Posts Upbeat Earnings
Healthcare Services Posts Upbeat Q3 Earnings, Joins Pool, Spotify And Other Big Stocks Moving Higher On Thursday Pharming Narrows FY2026 Sales Guidance from $375.000M-$395.000M to $380.000M-$390.000M vs $389.333M Est
Pharming Reports Preliminary Q3 Revenues $117.6M, Up 21% YoY; Operating Expenses $74.6M Vs $74.5M YoY; Napazimone FALCON Trial Enrollment Now Expected Complete In First Half 2027, 2026 Revenue Guidance Tightened To $380M-$390M From $375M-$395M
Your note
Sign in to keep a note on PHAR — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Silverberg Bernstein Capital Management LLC | 0.06% | 41,547 | 589.14K | Jun 29, 2026 |
| Smartharvest Portfolios, LLC | 0.02% | 10,797 | 153.10K | Mar 30, 2026 |
| Morgan Stanley | 0.02% | 11,489 | 162.91K | Mar 30, 2026 |
| Citadel Advisors Llc | 0.01% | 10,189 | 144.48K | Mar 30, 2026 |
| Knoll Capital Management, LLC | 0.01% | 4,057 | 57.53K | Mar 30, 2026 |
| Nalls Sherbakoff Group, Llc | 0.00% | 870 | 12.34K | Dec 30, 2025 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Steward Funds Inc-Steward Values Enhanced International Fund | 0.02% | 12,463 | 176.72K | Apr 29, 2026 |
| Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 0.00% | 2,093 | 29.68K | May 30, 2026 |
